Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | F2 | P00734 | 1/20 | 0.82 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77782 | 0.97 | F10 (0.86) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL2188917 | 0.92 | F10 (0.94) | F10ABCB11F2ST14 | |
| Rivaroxaban SCHEMBL7721848 | 0.90 | F10 (1.00) | F10ABCB11F2ST14CYP3A4 | |
| Rivaroxaban SCHEMBL77766 | 0.90 | F10 (1.00) | F10ABCB11F2ST14CYP3A4 | |
| Rivaroxaban SCHEMBL3914 | 0.90 | F10 (1.00) | F10ABCB11F2ST14CYP3A4 | |
| Rivaroxaban SCHEMBL14796329 | 0.90 | F10 (0.98) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL79087 | 0.89 | F10 (0.85) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL79766 | 0.89 | F10 (1.00) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL76791 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 | |
| SCHEMBL7247311 | 0.89 | F10 (1.00) | F10ABCB11F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | ROHRIG SUSANNE | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184767-A1 | SUBSTITUTED OXAZOLIDINONES AND USE THEREOF | XDH, OXA1L, PPOX | F10 391/4885ABCB11 725/4885F2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.